Biotech Cos. Must Respect Coexisting Gene Editing Patents

By Tyler Cho, John Emanuele, Roberta Hanson and David Walker (September 18, 2018, 2:53 PM EDT) -- A legal dispute over the fundamental patent rights to CRISPR-Cas9 gene editing technology might be coming to an end. On Monday, Sept. 10, the U.S. Court of Appeals for the Federal Circuit affirmed the decision of the U.S. Patent and Trademark Office, dismissing a challenge by the University of California, Berkeley, on CRISPR-Cas9 technology.

In its decision in favor of the Broad Institute, the Federal Circuit determined that "the [USPTO] did not err in concluding that Broad [Institute of MIT and Harvard]'s claims would not have been obvious over UC's claims." The decision will have wide implications — both for researchers...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!